Trials (Kortrijk Cancer Centre AZ Groeninge)

Go back to Kortrijk Cancer Centre AZ Groeninge page

NCTID: NCT01332968

Title: A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Study Summary: This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab maintenance in participants with untreated advanced indolent non-Hodgkin's lymphoma. After the end of the induction period, participants achieving response (Complete response \[CR\] or partial response \[PR\]) will undergo a maintenance period continuing on the randomized antibody treatment alone every 2 months until disease progression for a total of 2 years. Anticipated time on study treatment is up to approximately 2.5 years. After maintenance or observation, participants will be followed for 5 years until progression. After progression, participants will be followed for new anti-lymphoma therapy and overall survival until the end of the study.
Sponsor: Hoffmann-La Roche
Intervention: Obinutuzumab
Start Date: 2011-07-06
Last Updated: 2022-08-11
Number of Patients: 1401
Recruitment Status: COMPLETED
Condition: Non-Hodgkin's Lymphoma

NCTID: NCT00774345

Title: A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
Study Summary: The purpose of this study is to determine if lenalidomide (Revlimid®) is safe and effective as a maintenance therapy at improving further the quality of the response you achieved with your last therapy and at prolonging the duration of your response. This study will compare the effects (good and bad) of lenalidomide with the dummy drug.
Sponsor: Celgene
Intervention: Lenalidomide
Start Date: 2009-01-27
Last Updated: 2021-12-02
Number of Patients: 317
Recruitment Status: COMPLETED
Condition: B-cell Chronic Lymphocytic Leukemia

NCTID: NCT04987203

Title: Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
Study Summary: This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint Inhibitor (ICI).
Sponsor: AVEO Pharmaceuticals, Inc.
Intervention: Tivozanib
Start Date: 2021-09-09
Last Updated: 2023-10-27
Number of Patients: 326
Recruitment Status: ACTIVE_NOT_RECRUITING
Condition: Renal Cell Carcinoma

NCTID: NCT05947903

Title: Validation of the European Oncology Quality of Life Toolkit
Study Summary: The improvement or preservation of quality of life (QoL) is one of the three pillars of the European Union (EU) Mission on Cancer, which underpins the needs of patients from cancer diagnosis throughout treatment, survivorship, and advanced terminal stages. Clinical studies and real-world data show that the use of Patient Reported Outcome Measures (PROMs) for QoL assessment in routine oncology practice has positive effects on patient wellbeing and healthcare resource utilization. However, full implementation of PROMs is not yet part of standard of care and is not adequately considered in cancer policies and programs.A comprehensive tool incorporating the perspective of patients at different stages of the disease trajectory and widely applicable across Europe is still lacking.The European Oncology Quality of Life Toolkit (EUonQoL-Kit) is a unified patient-centred tool for the assessment of QoL, developed from preferences and priorities of people with past or current cancer experience. The EUonQoL-Kit includes three electronic questionnaires, specifically designed for different disease phases (patients in active treatment, survivors, and patients in palliative care), available in both static and dynamic (Computer Adaptive Testing, CAT) versions and in several European languages.This is a multicentre observational study, with the following aims:* The primary aim is to perform the psychometric validation of the EUonQoL-Kit.* Secondary aims are to assess its acceptability, to validate the CAT version, and to provide estimates of QoL across different European countries.The EUonQoL-Kit will be administered to a sample of cancer patients and survivors from 46 European cancer centres. The sample will include patients in active treatment (group A), survivors (group B), and patients in Palliative Care (group C).Each centre will recruit 100 patients (40 from group A, 30 from group B, 30 from group C), for an overall sample size of 4,600 patients (at least 4,000 patients are assumed to be enrolled, due to an expected lower recruitment rate of 10-15%). Three sub-samples of patients (each corresponding to 10% of the total sample for each centre) will fill in an additional questionnaire:* EORTC QLQ-C30, to test concurrent validity.* Live-CAT version, to test the feasibility of such implementation.* EUonQoL-Kit, 2-7 days after the first completion, to assess test-retest reliability.
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Intervention: Administration of the EUonQoL-Kit - Active Treatment questionnaire
Start Date: 2024-04-01
Last Updated: 2023-07-19
Number of Patients: 4000
Recruitment Status: NOT_YET_RECRUITING
Condition: Cancer

NCTID: NCT00089856

Title: GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
Study Summary: The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.
Sponsor: Cell Genesys
Intervention: Immunotherapy with allogeneic prostate vaccine
Start Date: 2004-07
Last Updated: 2008-11-05
Number of Patients: 626
Recruitment Status: TERMINATED
Condition: Prostate Cancer